Diabetic Neuropathy ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Diabetic Neuropathy ' Pipeline Review, H2 2012
Published on September 2012

Report Summary


Summary

Global Markets Direct's, 'Diabetic Neuropathy - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic development for Diabetic Neuropathy, complete with latest updates, and
special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Diabetic Neuropathy. Diabetic Neuropathy - Pipeline Review, Half Year is built using data and information sourced from Global
Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Neuropathy.
- A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Neuropathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Diabetic Neuropathy ' Pipeline Review, H2 2012 (From Slideshare) Page 1/8


Table of Content

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathy Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diabetic Neuropathy 10
Diabetic Neuropathy Therapeutics under Development by Companies 12
Diabetic Neuropathy Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Pre-Clinical Stage Products 17
Diabetic Neuropathy Therapeutics ' Products under Development by Companies 18
Diabetic Neuropathy Therapeutics ' Products under Investigation by Universities/Institutes 19
Companies Involved in Diabetic Neuropathy Therapeutics Development 20
Daiichi Sankyo Company, Ltd 20
Merck & Co., Inc. 21
Dainippon Sumitomo Pharma Co., Ltd. 22
Takeda Pharmaceutical Company Limited 23
Dong-A Pharmaceutical Co., Ltd. 24
Lpath, Inc. 25
NeurogesX, Inc. 26
Diamyd Medical AB 27
R-Tech Ueno, Ltd. 28
Neurotune AG 29
Arcion Therapeutics, Inc. 30
Taiwan Liposome Company 31
Viromed Co., Ltd. 32
Cebix Incorporated 33
TheraQuest Biosciences, LLC 34
Beech Tree Labs, Inc. 35
Diabetic Neuropathy ' Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
ranirestat - Drug Profile 42
Product Description 42



Mechanism of Action 42
R&D Progress 42
ranirestat - Drug Profile 43
R&D Progress 43
TAK-428 - Drug Profile 44
R&D Progress 44
Lpathomab - Drug Profile 45
R&D Progress 45
iroxanadine - Drug Profile 46
R&D Progress 46
NT-13317 - Drug Profile 48
R&D Progress 48
NG2-GAD - Drug Profile 49
R&D Progress 49
tapentadol hydrochloride ER - Drug Profile 50
R&D Progress 50
capsaicin - Drug Profile 53
R&D Progress 53
VM-202 - Drug Profile 54
R&D Progress 54
RTU-1096 - Drug Profile 56
R&D Progress 56
Allopurinal + Alpha Lipoic Acid + Nicotinamide - Drug Profile 57
R&D Progress 57
clonidine hydrochloride - Drug Profile 59



R&D Progress 59
Cannabis Based Medicine Extract - Drug Profile 61
R&D Progress 61
DA-3030 - Drug Profile 62
R&D Progress 62
MK-6096 - Drug Profile 63
R&D Progress 63
alprostadil - Drug Profile 64
R&D Progress 64
Vascular Endothelial Growth Factor - Drug Profile 65
R&D Progress 65
Drug For Neuropathy - Drug Profile 66
R&D Progress 66
DS-5565 - Drug Profile 67
R&D Progress 67
mepivacaine - Drug Profile 68
R&D Progress 68
NT-24336 - Drug Profile 70
R&D Progress 70
Ersatta - Drug Profile 71
R&D Progress 71
DA-9801 - Drug Profile 74
R&D Progress 74
Rosuvastatin - Drug Profile 75



R&D Progress 75
Diabetic Neuropathy Therapeutics ' Drug Profile Updates 76
Diabetic Neuropathy Therapeutics ' Discontinued Products 83
Diabetic Neuropathy Therapeutics - Dormant Products 84
Diabetic Neuropathy ' Product Development Milestones 85
Featured News & Press Releases 85
Aug 29, 2012: RegeneRx Reports That Thymosin Beta 4 Promotes Recovery Of Peripheral Neuropathy In Type II Diabetic Mice 85
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 85
May 04, 2012: Pfizer Reports Top-Line Results From Phase III Trial Of Lyrica Capsules CV In Patients With Diabetic Peripheral
Neuropathy 86
Mar 20, 2012: Astellas Pharma Europe Withdraws Its Applications For Extension Of Indication For Qutenza 86
Feb 21, 2012: SK Biopharmaceuticals Initiates Phase II Trials In US 87
Nov 07, 2011: NephroGenex Reaches Agreement With FDA On Subpart H Phase III Program For Pyridorin 87
Oct 31, 2011: J&JPRD Submits Supplemental New Drug Application To FDA For NUCYNTA ER Tablets For Diabetic Peripheral
Neuropathic Pain 88
Oct 19, 2011: Concert Pharmaceuticals To Present Data On CTP-499 At American Society of Nephrology Kidney Week Meeting 88
Oct 11, 2011: Antisense Completes Dosing In ATL1103 Phase I Clinical Trial 89
Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual
NEURODIAB Meeting 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Tables

Number of Products Under Development for Diabetic Neuropathy, H2 2012 10
Products under Development for Diabetic Neuropathy ' Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Daiichi Sankyo Company, Ltd, H2 2012 20
Merck & Co., Inc., H2 2012 21
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 22
Takeda Pharmaceutical Company Limited, H2 2012 23
Dong-A Pharmaceutical Co., Ltd., H2 2012 24
Lpath, Inc., H2 2012 25
NeurogesX, Inc., H2 2012 26
Diamyd Medical AB, H2 2012 27



R-Tech Ueno, Ltd., H2 2012 28
Neurotune AG, H2 2012 29
Arcion Therapeutics, Inc., H2 2012 30
Taiwan Liposome Company, H2 2012 31
Viromed Co., Ltd., H2 2012 32
Cebix Incorporated, H2 2012 33
TheraQuest Biosciences, LLC, H2 2012 34
Beech Tree Labs, Inc., H2 2012 35
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 41
Diabetic Neuropathy Therapeutics ' Drug Profile Updates 76
Diabetic Neuropathy Therapeutics ' Discontinued Products 83
Diabetic Neuropathy Therapeutics ' Dormant Products 84

List of Figures

Number of Products under Development for Diabetic Neuropathy, H2 2012 10
Products under Development for Diabetic Neuropathy ' Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Route of Administration, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Molecule Type, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 41


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Diabetic Neuropathy ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Diabetic Neuropathy ' Pipeline Review, H2 2012